Management of relapsed multiple myeloma after autologous stem cell transplant

Sarah A Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L. McCarthy

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma patients who are eligible to receive high-dose therapy, recognizing that the optimal timing and integration of this approach is now under study in a number of randomized trials. Despite the improved response rates with induction therapy consisting of immunomodulatory drugs and/or proteasome inhibitors, as well as the increasing use of post-ASCT maintenance therapy, most myeloma patients relapse and die of their disease. Here we discuss the options for managing post-ASCT relapse, including the role of various salvage regimens in the setting of relapsed and refractory myeloma, salvage ASCT, and salvage allogeneic SCT.

Original languageEnglish (US)
Pages (from-to)793-798
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume21
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Stem Cells
Transplants
Recurrence
Proteasome Inhibitors
Immunomodulation
Standard of Care
Therapeutics
Pharmaceutical Preparations

Keywords

  • Monoclonal antibody
  • Multiple myeloma salvage autologous stem cell transplant
  • Relapsed/refractory
  • Salvage allogenic stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Management of relapsed multiple myeloma after autologous stem cell transplant. / Holstein, Sarah A; Richardson, Paul G.; Laubach, Jacob P.; McCarthy, Philip L.

In: Biology of Blood and Marrow Transplantation, Vol. 21, No. 5, 01.05.2015, p. 793-798.

Research output: Contribution to journalReview article

Holstein, Sarah A ; Richardson, Paul G. ; Laubach, Jacob P. ; McCarthy, Philip L. / Management of relapsed multiple myeloma after autologous stem cell transplant. In: Biology of Blood and Marrow Transplantation. 2015 ; Vol. 21, No. 5. pp. 793-798.
@article{55e82918dd22406abec742c095778257,
title = "Management of relapsed multiple myeloma after autologous stem cell transplant",
abstract = "Autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma patients who are eligible to receive high-dose therapy, recognizing that the optimal timing and integration of this approach is now under study in a number of randomized trials. Despite the improved response rates with induction therapy consisting of immunomodulatory drugs and/or proteasome inhibitors, as well as the increasing use of post-ASCT maintenance therapy, most myeloma patients relapse and die of their disease. Here we discuss the options for managing post-ASCT relapse, including the role of various salvage regimens in the setting of relapsed and refractory myeloma, salvage ASCT, and salvage allogeneic SCT.",
keywords = "Monoclonal antibody, Multiple myeloma salvage autologous stem cell transplant, Relapsed/refractory, Salvage allogenic stem cell transplant",
author = "Holstein, {Sarah A} and Richardson, {Paul G.} and Laubach, {Jacob P.} and McCarthy, {Philip L.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.bbmt.2014.12.026",
language = "English (US)",
volume = "21",
pages = "793--798",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Management of relapsed multiple myeloma after autologous stem cell transplant

AU - Holstein, Sarah A

AU - Richardson, Paul G.

AU - Laubach, Jacob P.

AU - McCarthy, Philip L.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma patients who are eligible to receive high-dose therapy, recognizing that the optimal timing and integration of this approach is now under study in a number of randomized trials. Despite the improved response rates with induction therapy consisting of immunomodulatory drugs and/or proteasome inhibitors, as well as the increasing use of post-ASCT maintenance therapy, most myeloma patients relapse and die of their disease. Here we discuss the options for managing post-ASCT relapse, including the role of various salvage regimens in the setting of relapsed and refractory myeloma, salvage ASCT, and salvage allogeneic SCT.

AB - Autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma patients who are eligible to receive high-dose therapy, recognizing that the optimal timing and integration of this approach is now under study in a number of randomized trials. Despite the improved response rates with induction therapy consisting of immunomodulatory drugs and/or proteasome inhibitors, as well as the increasing use of post-ASCT maintenance therapy, most myeloma patients relapse and die of their disease. Here we discuss the options for managing post-ASCT relapse, including the role of various salvage regimens in the setting of relapsed and refractory myeloma, salvage ASCT, and salvage allogeneic SCT.

KW - Monoclonal antibody

KW - Multiple myeloma salvage autologous stem cell transplant

KW - Relapsed/refractory

KW - Salvage allogenic stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=84928214227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928214227&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.12.026

DO - 10.1016/j.bbmt.2014.12.026

M3 - Review article

VL - 21

SP - 793

EP - 798

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -